Positive top-line data for Forest/Richter's antipsychotic cariprazine as filing nears
This article was originally published in Scrip
Executive Summary
Forest Laboratories and Gedeon Richter have confirmed plans to file for approval of the investigational atypical antipsychotic, cariprazine (RGH-188), in the two indications of schizophrenia and bipolar mania in 2012.